In a nutshell This trial is looking at the effectiveness, safety, and tolerability of ladiratuzumab vedotin (LV) in patients with advanced solid tumors, including prostate cancer. The main outcome to be measured in this trial is the response rate to the new drug. The details Advanced tumors have spread from the organ where they originated. These...
Read MoreType of prostate cancer-Adenocarcinoma Posts on Medivizor
The importance of timing of radiotherapy after radical prostatectomy in patients with prostate cancer
In a nutshell The study compared outcomes of adjuvant radiotherapy (AR) versus observation with salvage radiotherapy (SR) in patients with prostate cancer (PCa) after radical prostatectomy (RP). The authors found that careful observation with SR is a safer treatment after RP for preventing cancer progression. Some background RP surgically removes the...
Read MoreQuality of life in patients with metastatic prostate cancer under cabazitaxel treatment
In a nutshell The study compared the quality of life (QoL) of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (Jevtana) compared to abiraterone (Zytiga) or enzalutamide (Xtandi). The authors found that cabazitaxel did not reduce QoL in such patients. Some background Patients with mCRPC...
Read MoreIpilimumab and radiotherapy improves survival in patients with metastatic castration-resistant prostate cancer
In a nutshell This trial was carried out to examine the effectiveness of radiotherapy followed by treatment with ipilimumab (Yervoy) in men with metastatic castrate-resistant prostate cancer (mCRPC). The trial found that this treatment led to higher survival in these patients compared to radiotherapy followed by placebo. Some...
Read MoreDoes a dose of 20 or 25 mg/m2 of cabazitaxel benefit patients with castration-resistant prostate cancer?
In a nutshell This study aimed to assess the effectiveness and safety of two doses of cabazitaxel (Jevtana) (20 or 25 mg/m2) in the treatment of castration-resistant prostate cancer (CRPC) in the real-world practice. The study found that a lower dose of cabazitaxel benefited patients at high risk of having side...
Read MoreLooking for patients with high risk prostate cancer to trial a radiation treatment
In a nutshell This trial is aiming to investigate the effectiveness of stereotactic body radiotherapy (SBRT) boost for the treatment in patients with high-risk prostate cancer (PCa). The main outcome that will be measured will be the quality of life (QoL) of patients. This study is being carried out in Ontario, Canada. The details PCa is the...
Read MoreA comparison of high-dose vs. moderate-dose SBRT for prostate cancer.
In a nutshell This study was carried out to assess different dosing regimens of hypofractionated stereotactic body radiotherapy (SBRT) in patients with prostate cancer. The study found that both doses were associated with high effectiveness and manageable side effects. Some background Radiotherapy is an effective treatment for early-stage PC....
Read MoreCan high-risk prostate cancer be treated with high-dose-rate brachytherapy, external beam radiotherapy plus long-term androgen deprivation therapy?
In a nutshell This study looked at whether the use of high-dose (HD) brachytherapy (BT) and hypofractionated external beam radiotherapy (EBRT) plus androgen-deprivation therapy (ADT) as a means of treatment for very high-risk prostate cancer (PCa). The study found that this treatment had significant benefits for patients with high-risk...
Read MoreThe effects of bipolar androgen therapy in men with metastatic castration resistant prostate cancer
In a nutshell The study evaluated outcomes of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) who were continuing drugs targeting androgen receptors (AR). The authors found that BAT was clinically effective in such patients. Some background BAT refers to sequential injections with testosterone in men...
Read MoreComparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer
In a nutshell The study compared the long-term effects of moderate hypofractionated intensity-modulated radiation therapy (H-IMRT) and conventionally fractionated IMRT (C-IMRT) on outcomes in patients with localized prostate cancer (PC). The authors found that H-IMRT was similarly effective compared to C-IMRT after 10 years of therapy in such...
Read MoreCan oral relugolix be used as androgen-deprivation therapy in advanced prostate cancer?
In a nutshell The study looked at whether oral relugolix (Orgovyx, Relumina) could be used to suppress testosterone in men with advanced prostate cancer compared to leuprolide (Lupron). This study showed that relugolix was associated with more rapid and effective suppression of testosterone levels when compared...
Read MoreShould androgen-deprivation therapy be given at the same time or before radiotherapy in the treatment of localized prostate cancer?
In a nutshell The study looked at the sequence of dose-escalated radiotherapy (RT) and androgen-deprivation therapy (ADT) in the treatment of local prostate cancer (LPCa). The study found that treatment with ADT before RT had the same outcome as treatment with ADT and RT at the same time. Some background LPCa is a form of cancer that is...
Read More